Enliven Therapeutics (ELVN) Net Cash Flow (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Net Cash Flow data on file, last reported at $33.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 248.17% year-over-year to $33.3 million; the trailing twelve-month figure through Mar 2026 stood at $30.5 million (up 164.15% YoY), and the FY2025 full-year result was -$25.3 million, down 205.42% from the prior year.
• Net Cash Flow climbed to $33.3 million in Q1 2026, from -$2.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $216.6 million in Q1 2023 to a low of -$166.4 million in Q2 2023.
• A 5-year average of $1.3 million and a median of -$6.3 million in 2022 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 2234.5% in 2023, while the deepest fall reached 2141.81% in 2023.
• Tracing ELVN's Net Cash Flow over 5 years: stood at -$10.6 million in 2022, then jumped by 347.52% to $26.3 million in 2023, then decreased by 10.64% to $23.5 million in 2024, then tumbled by 112.07% to -$2.8 million in 2025, then surged by 1273.77% to $33.3 million in 2026.
• Business Quant data shows ELVN's Net Cash Flow at $33.3 million in Q1 2026, -$2.8 million in Q4 2025, and -$17.7 million in Q3 2025.